<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634491</url>
  </required_header>
  <id_info>
    <org_study_id>2438</org_study_id>
    <nct_id>NCT00634491</nct_id>
  </id_info>
  <brief_title>Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy</brief_title>
  <official_title>Effect of Acetazolamide in Prevention of Contrast Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fars Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is whether Acetazolamide is effective in prevention of contrast
      nephropathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Contrast induced nephropathy is one of common causes of acute renal failure many preventive
      protocol existed . 240 patient that underwent coronary angiography randomly divided in three
      groups.Group 1,2,3 will receive Bicarbonate ,Acetazolamide+Normal salin and Normal salin
      respectively.We compare prevalence of contrast nephropathy in each group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increased base line creatinine at least 25%</measure>
    <time_frame>24 hr later</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Contrast Induced Nephropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 meq/l NaHco3 3cc/kg/hr one Hour before and 1cc/kg/hr 6 hour after angiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetazolamide 250 mg + 1cc/kg/hr normal salin 6 hour before and after angiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>normal salin 1cc/kg/hr before and after angiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium bicarbonate</intervention_name>
    <description>150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography</description>
    <arm_group_label>1</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Diamox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal salin</intervention_name>
    <description>1 cc/kg/hr 6 hour before and after angiography</description>
    <arm_group_label>3</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient that underwent coronary angiography

        Exclusion Criteria:

          -  serum Cr. more than 3 mg/dl

          -  electrolyte and acid-base imbalance

          -  pulmonary edema

          -  allergy to Acetazolamide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryam Pakfetrat, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shiraz nephro-urology research center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fars Heart Foundation , Kowsar hospital</name>
      <address>
        <city>Shiraz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.pubmed.com</url>
  </link>
  <results_reference>
    <citation>Assadi F. Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug. Pediatr Cardiol. 2006 Mar-Apr;27(2):238-42.</citation>
    <PMID>16391986</PMID>
  </results_reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>March 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <last_update_submitted>March 4, 2008</last_update_submitted>
  <last_update_submitted_qc>March 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Office of Vice Chancellor for research in Shiraz UMS</name_title>
    <organization>Shiraz University of Medical Science</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

